For more than 10 years, the FHI Clinical project team has partnered with companies developing and deploying vaccines, treatments and preventive devices for malaria in 35 countries worldwide.
FHI Clinical has long-standing relationships, a local team and broad expertise in sub-Saharan Africa. We're ready to help you confidently expand your research across the region, finding the best-fit countries and populations for your target indication and study type.
Since 1976, Ebola virus disease outbreaks have primarily occurred in eleven countries: Democratic Republic of the Congo, Gabon, Guinea, Liberia, Mali, Nigeria, Republic of Congo, Sierra Leone, Sudan and Uganda. Although it is generally rare, it is often fatal, with death rates ranging from 25 to 90% in past outbreaks (average case fatality rate, 50%). No treatment or vaccine is currently approved, but there are several promising vaccines and treatments under development.
Within a challenging, resource-limited setting, the project team succeeded in reaching FP/FV six weeks after arrival in Sierra Leone and 99.998% accuracy of the planned-to-execute budget.
In a Phase 3 study with a lengthy intervention for colorectal cancer, the project team reached a 70% retention rate, with steadily increasing enrollment rates, by implementing strategies to address poor patient enrollment and retention.
FHI Clinical goes where our expertise is needed. Whether it requires working from a state-of-the-art facility or in a low-tech, rural setting, we provide services tailored to meet your study needs, from protocol design and site assessments to trial planning, implementation and management.